Intercept’s NASH hopes dashed
Sign Up to like & getrecommendations! Published in 2020 at "Nature Biotechnology"
DOI: 10.1038/s41587-020-0638-5
Abstract: NAtURe BioteChNology | VOL 38 | AuguST 2020 | 905–916 | www.nature.com/naturebiotechnology EZH2 drug resistance in lymphoma is also a puzzle. Later-stage tumors, under the pressure of therapy, may develop clones that can tolerate the… read more here.
Keywords: intercept nash; ezh2 inhibitor; ezh2 inhibitors; ezh2 ... See more keywords
Convection-Enhanced Delivery of Enhancer of Zeste Homolog-2 (EZH2) Inhibitor for the Treatment of Diffuse Intrinsic Pontine Glioma.
Sign Up to like & getrecommendations! Published in 2020 at "Neurosurgery"
DOI: 10.1093/neuros/nyaa301
Abstract: BACKGROUND Diffuse intrinsic pontine glioma (DIPG) is a fatal childhood brain tumor and the majority of patients die within 2 yr after initial diagnosis. Factors that contribute to the dismal prognosis of these patients include… read more here.
Keywords: diffuse intrinsic; ezh2 inhibitor; inhibitor; intrinsic pontine ... See more keywords
EZH2 Inhibitor GSK126 Suppresses Antitumor Immunity by Driving Production of Myeloid-Derived Suppressor Cells.
Sign Up to like & getrecommendations! Published in 2019 at "Cancer research"
DOI: 10.1158/0008-5472.can-18-2395
Abstract: Enhancer of zeste homolog (EZH2) is a key epigenetic regulator of gene expression and is frequently overexpressed in various cancer types, suggesting a role in oncogenesis. The therapeutic potential of EZH2 inhibitors is currently being… read more here.
Keywords: antitumor immunity; gsk126; ezh2 inhibitor; inhibitor gsk126 ... See more keywords
Epithelioid Sarcoma Responds to the Oral EZH2 Inhibitor Tazemetostat.
Sign Up to like & getrecommendations! Published in 2020 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-rw2020-151
Abstract: Tazemetostat produced an overall response rate of 15% and median overall survival of 19.0 months. read more here.
Keywords: ezh2 inhibitor; sarcoma responds; responds oral; oral ezh2 ... See more keywords
BET-bromodomain and EZH2 inhibitor treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes.
Sign Up to like & getrecommendations! Published in 2022 at "Blood"
DOI: 10.1182/blood.2021014557
Abstract: Despite advances in the field, chronic graft-vs-host-disease (cGVHD) remains a leading cause of morbidity and mortality following allogenic hematopoietic stem cell transplant. As treatment options remain limited, we tested efficacy of anti-cancer, chromatin modifying enzyme… read more here.
Keywords: ezh2 inhibitor; jq5; bet bromodomain; inhibitor ... See more keywords
A Facile Total Synthesis of Kilogram-Scale Production of SKLB1039: A Novel and Selective Hexahydroisoquinolin-Containing EZH2 Inhibitor.
Sign Up to like & getrecommendations! Published in 2022 at "Current organic synthesis"
DOI: 10.2174/1570179419666220107161257
Abstract: BACKGROUND SKLB1039 is a potent, highly selective, and orally bioavailable EZH2 inhibitor, which significantly inhibited breast tumor growth and metastasis, in pre-clinical studies. In a previously reported synthesis of SKLB1039, the yields of several steps… read more here.
Keywords: ezh2 inhibitor; sklb1039; scale; production sklb1039 ... See more keywords
Validation of EZH2 Inhibitor Efficiency in Anaplastic Thyroid Carcinoma Cell Lines
Sign Up to like & getrecommendations! Published in 2023 at "AntiCancer Research"
DOI: 10.21873/anticanres.16252
Abstract: Background/Aim: The prognosis of anaplastic thyroid carcinoma (ATC) is poor, and there is currently no established treatment to improve its outcome. We previously reported that enhancer of zeste homolog 2 (EZH2) was highly expressed in… read more here.
Keywords: cell lines; atc cell; cell; ezh2 inhibitor ... See more keywords